Investors pour $370M+ into Ken Song’s autoimmune biotech after his RayzeBio success

Ken Song knows how to step on the gas ped­al.

His new com­pa­ny, called Can­did Ther­a­peu­tics, emerged from stealth on Mon­day morn­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.